Investigating a new treatment for liver diseases using specific kinase inhibitors
USE OF DYRK1A/B KINASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
This study is testing a new treatment called ABI-171 for people with nonalcoholic fatty liver disease (NAFLD) and its more serious form, NASH, to see if it can help improve liver health by reducing inflammation and scarring.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Avanti Biosciences, INC. NIH-funded |
| Lab location | 1 site (East Setauket, United States) |
| Project ID | NIH-10696380 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for nonalcoholic fatty liver disease (NAFLD) and its aggressive form, nonalcoholic steatohepatitis (NASH). The study will evaluate a novel compound, ABI-171, which targets specific kinases involved in liver inflammation and fibrosis. By assessing how this compound accumulates in the liver and its effects on liver health, the research aims to provide a safe and effective pharmacological option for patients suffering from these conditions. The approach includes both biochemical and cellular assays, as well as animal models to test efficacy and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
Not a fit: Patients with liver diseases caused by alcohol consumption or other non-metabolic factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new medication that effectively treats liver diseases, potentially reducing the need for liver transplants.
How similar studies have performed: While there is ongoing research in this area, the specific approach using DYRK1A/B kinase inhibitors is relatively novel and has not been extensively tested in humans.
Where this research is happening
East Setauket, United States
- Avanti Biosciences, INC. — East Setauket, United States (Active)
Researchers
- Principal investigator: Araldi, Gian Luca — Avanti Biosciences, INC.
- Study coordinator: Araldi, Gian Luca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.